Form 4 for MRK Merck & Co.

Accepted 2021-11-02 00:00:00 ET · period of report 2021-10-30 · accession 0001127602-21-028163 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-11-02	2021-10-30	MRK	MIZELL STEVEN	EVP, Chief HR Off	F - Tax	$88.05	-2,323	25.6K	-8%	-$204.5K
D	2021-11-02	2021-10-30	MRK	MIZELL STEVEN	EVP, Chief HR Off	M - OptEx	$88.05	+4,715	27.9K	+20%	+$415.2K
D	2021-11-02	2021-10-30	MRK	MIZELL STEVEN	EVP, Chief HR Off	M - OptEx	$0.00	-4,715	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-10-30	F	D	2,323	$88.05	25,573.15	D	—	—	(F1) Holdings include shares acquired in dividend reinvestment transactions.
2	Common	Common Stock	2021-10-30	M	A	4,715	$88.05	27,896.15	D	—	—
3	Derivative	Restricted Stock Unit	2021-10-30	M	D	4,715	$0.00	0	D	— · 2019-10-30 to 2021-10-30	4,715 Common Stock	(F3) Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. (F2) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. (F4) The restricted stock units vested and were distributed in equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.